Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trialPUBT·Jul 7 at 07:01 AMTOVX+2.72%
Theriva Biologics shares are trading higher after the company announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.benzinga_article·Jun 11 at 07:46 AMTOVX+2.72%
Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)Tip Ranks·May 6 at 06:38 AMTOVX+2.72%IBBQ-0.55%
Theriva Q1 Net Loss Narrows; Plans Dosing Feasibility Study Of VCN-01 In H2,2026;Stock Downnasdaq·May 6 at 04:35 AMTOVX+2.72%ARKG-2.60%
Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy ApproachesMorningStar·May 4 at 02:05 AMNBSE.ESCTOVX+2.72%
U.S. stock market midday update: Theriva Biologics stock price plummets 23.22%, market reacts lukewarm to clinical trial data?Price Alert·Apr 21 at 09:03 AMTOVX+2.72%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Apr 21 at 07:05 AMATRA-3.30%TVGNW+1.18%
Pre-market hot trades in US stocks: Aevex up 12.24% pre-market; Theriva Biologics down 11.78% pre-marketPrice Alert·Apr 21 at 03:28 AMAVEX-5.55%TOVX+2.72%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Apr 20 at 07:05 AMPBM+4.61%ENVB-2.27%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Apr 20 at 12:05 PMTOVX+2.72%PASG+0.82%
